Source comparison
TB-500 Research Andropause Considerations: Quick Comparison
Testosterone Replacement Therapy (TRT) Androgen receptor activation Libido, energy, muscle mass, mood High. Multiple RCTs 4–6 weeks for subjective effects; 12+ weeks for body composition Gold standard for hormonal deficits; requires monitoring for cardiovascul
This comparison does not assign a generated winner or score.
- Testosterone Replacement Therapy (TRT)
- Androgen receptor activation
- Libido, energy, muscle mass, mood
- High. Multiple RCTs
- 4–6 weeks for subjective effects; 12+ weeks for body composition
- Gold standard for hormonal deficits; requires monitoring for cardiovascular and prostate risks
- TB-500 Peptide
- Actin-binding; promotes cell migration and angiogenesis
- Joint mobility, tissue repair, exercise recovery, cardiovascular perfusion
- Low. Animal models and case reports only
- 2–4 weeks for tissue-level effects; 8–12 weeks for functional outcomes
- Mechanistically plausible for repair pathways; lacks human RCT evidence for andropause-specific outcomes
- Growth Hormone Secretagogues (e.g., MK-677)
- Stimulates endogenous GH and IGF-1 release
- Sleep quality, recovery, lean mass retention
- Moderate. Phase II/III trials in non-andropause populations
- 4–8 weeks for metabolic effects
- Addresses recovery and anabolic signaling; side effect profile (edema, insulin resistance) limits long-term use
- Exercise + Nutritional Optimization
- Multi-pathway: insulin sensitivity, mitochondrial biogenesis, muscle protein synthesis
- Fatigue, body composition, cardiovascular health, mood
- High. Decades of RCT evidence
- 6–12 weeks for measurable outcomes
- Non-negotiable foundation; pharmaceutical or peptide interventions augment but don't replace lifestyle optimisation